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Abstract
Rationale: Human embryonic and induced pluripotent stem cells (hESCs/hiPSCs) are promising cell sources for cardiac
regenerative medicine. To realize hESC/hiPSC-based cardiac cell therapy, efficient induction, purification, and
transplantation methods for cardiomyocytes are required. Though marker gene transduction or fluorescent-based
purification methods have been reported, fast, efficient and scalable purification methods with no genetic modification are
essential for clinical purpose but have not yet been established. In this study, we attempted to identify cell surface markers
for cardiomyocytes derived from hESC/hiPSCs.
Method and Result: We adopted a previously reported differentiation protocol for hESCs based on high density monolayer
culture to hiPSCs with some modification. Cardiac troponin-T (TNNT2)-positive cardiomyocytes appeared robustly with 30–
70% efficiency. Using this differentiation method, we screened 242 antibodies for human cell surface molecules to isolate
cardiomyocytes derived from hiPSCs and identified anti-VCAM1 (Vascular cell adhesion molecule 1) antibody specifically
marked cardiomyocytes. TNNT2-positive cells were detected at day 7–8 after induction and 80% of them became VCAM1-
positive by day 11. Approximately 95–98% of VCAM1-positive cells at day 11 were positive for TNNT2. VCAM1 was exclusive
with CD144 (endothelium), CD140b (pericytes) and TRA-1-60 (undifferentiated hESCs/hiPSCs). 95% of MACS-purified cells
were positive for TNNT2. MACS purification yielded 5210610
5 VCAM1-positive cells from a single well of a six-well culture
plate. Purified VCAM1-positive cells displayed molecular and functional features of cardiomyocytes. VCAM1 also specifically
marked cardiomyocytes derived from other hESC or hiPSC lines.
Conclusion: We succeeded in efficiently inducing cardiomyocytes from hESCs/hiPSCs and identifying VCAM1 as a potent
cell surface marker for robust, efficient and scalable purification of cardiomyocytes from hESC/hiPSCs. These findings would
offer a valuable technological basis for hESC/hiPSC-based cell therapy.
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Introduction
Recent advances of stem cell biology have provided a basis of
novel regenerative therapy, in which human embryonic stem cells
(hESCs) and induced pluripotent stem cells (hiPSCs) can provide
cardiomyocytes for transplantation [1]. To establish hESC/
hiPSC-based cardiac cell therapy, efficient induction, purification
and transplantation methods for cardiomyocytes are required.
High differentiation efficiencies of cardiomyocytes (approximately
30–80%) have been reported in some protocols [1–3]. Neverthe-
less, these efficient methods still did not provide pure cardiomy-
ocytes. Contamination of undifferentiated hESC/hiPSCs would
cause teratoma formation after transplantation. Moreover, for
application of hESC/hiPSC-derived cardiomyocytes to clinical
purpose, large-scale purification with no genetic modification
would be required. Thus, the establishment of human cardiomy-
ocyte purification methods with cell surface markers has been long
awaited.
We have been investigating cardiovascular cell differentiation
and regeneration using mouse and human ESCs and iPSCs. We
reported a systematic cardiovascular cell differentiation method
with mouse iPSCs [4] and an enhancement method of hiPSC
differentiation to cardiomyocytes with an immunosuppressant,
cyclosporin-A [5]. In this study, to further improve differentiation
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23657efficiency of hiPSCs to cardiomyocytes and identify cell surface
markers for human cardiomyocytes, we adopted an efficient
differentiation method that was previously established in hESCs
[1] to hiPSCs with some modifications, and screened an antibody
library for human cell surface molecules with this modified
method. We succeeded in identifying CD106 (vascular cell
adhesion molecule 1/VCAM1) as a potent marker to efficiently
purify human cardiomyocytes derived from hESCs/hiPSCs.
Methods
hESC/hiPSC culture and differentiation
hESCs (KhES1) and hiPSCs (4-factor (Oct3/4, Sox2, Klf4, and
c-Myc) lines: 201B6, 201B7 and 3-factor (Oct3/4, Sox2, and Klf4)
lines: 253G1, 253G4) were established previously [6–8]. 201B6
Figure 1. Efficient induction of cardiomyocytes from hiPSCs. (A) Schematic representation of cardiomyocyte induction protocol. (B)
Expression profiles of cardiac troponin-T (TNNT2) during differentiation. Open line indicates isotype control and blue line indicates TNNT2 staining.
(C–F) qPCR of differentiation stage-specific genes. (C) Pluripotency marker genes (NANOG, POU5F1); normalized to d0 expression (D) Mesodermal
marker genes (T, MESP1); normalized to d2 expression (E) Cardiac progenitor genes (KDR, ISL1); normalized to d5 expression (F) Cardiac marker genes
(NKX2-5, MYH6, MYH7, MYL7, MYL2); normalized to d11 expression. Mean6SD, n=3.
doi:10.1371/journal.pone.0023657.g001
Table 1. Antibody list.
Antibody Conjugate Concentration Clone Maker
VCAM1 APC 1:200 STA BioLegend
PDGFRb PE 1:50 28d4 BD
VE-cadherin PE 1:50 55-7h1 BD
TRA-1-60 FITC 1:20 Tra-1-60 BD
APC: allophycocyanin, PE: phycoerythrin, FITC: Fluorescein isothiocianate.
doi:10.1371/journal.pone.0023657.t001
VCAM1 as a hESC/iPSC-Derived Cardiomyocyte Marker
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experiments unless stated otherwise. These cells were adapted and
maintained on thin-coat matrigel (Growth factor reduced; 1:60
dilution; Invitrogen) in mouse embryonic fibroblast conditioned
medium (MEF-CM) supplemented with 4 ng/mL human basic
fibroblast growth factor (hbFGF; WAKO) [9]. Cells were passaged
as small clumps once in every 4–6 days using CTK solution (0.1%
Collagenase IV, 0.25% Trypsin, 20% Knockout serum replace-
ment (KSR), and 1 mM CaCl2 in Phosphate buffered saline (PBS))
[6]. MEF cells were treated with Mitomycin-C (MMC) (WAKO)
for 2.5 hours, harvested and seeded at approximately 55,000 cells/
cm
2 in MEF medium (Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% fetal calf serum (FCS), 2 mM L-
glutamine, 1% nonessential amino acids (NEAA)). After 1 day, the
culture medium was exchanged with ES medium (80% KNOCK-
OUT–DMEM, 20% KSR, 1 mM L-glutamine, 0.1 mM b-
mercaptoethanol, 1% NEAA, and 4 ng/ml hbFGF; 0.5 mL/
cm
2). MEF-CM was collected daily for 7 days and supplemented
with an additional 4 ng/mL of hbFGF before feeding hES/hiPS
cells.
Cardiomyocyte differentiation was induced as previously
reported [1] with some modifications as shown in figure 1A
(modified-directed differentiation protocol). Cells were detached
by 3–5 min incubation with Versene (Invitrogen) and seeded onto
Matrigel-coated plates at a density of 10,000 cells/cm
2 in MEF-
CM plus 4 ng/mL bFGF for 2–3 days before induction. Cells were
covered with matrigel (1:60 dilution) on the day before induction.
To induce cardiac differentiation, we replaced MEF-CM with
RPMI+B27 medium (RPMI1640, 2 mM L-glutamine, x1 B27
supplement without insulin) supplemented with 100 ng/mL of
Activin A (ActA; R&D Systems) for 24 hours, followed by 10 ng/
mL human Bone morphogenetic protein 4 (BMP4; R&D) and
10 ng/mL hbFGF for 4 days with no culture medium replace-
ment. The culture medium was subsequently replaced with
RPMI+B27 supplemented with 100 ng/mL of Dkk1 for 2 days.
At day 7, the culture medium was changed to RPMI+B27 without
supplementary cytokines; culture medium was refreshed every 1–2
days. Beating cells appeared at day 8–9 and beating area spread by
day 11.
Flow Cytometry, Cell Sorting, and Fluorescent
Microscopy
Cells after hESC/hiPSC differentiation were dissociated by
incubation with Accumax (Innovative Cell Technologies) and
were stained with one of the markers listed in Table 1. For cell
surface markers, staining was carried out in PBS with 5% FCS.
To eliminate dead cells, cells were stained with 49,6-diamidino-2-
phenylindole (DAPI) for surface marker staining or with LIVE/
DEAD fixable Aqua dead cell staining kit (Invitrogen) for
intracellular staining. For intracellular proteins, staining was
carried out on cells fixed with 4% paraformaldehyde (PFA) in
PBS. Cells were stained with anti-cardiac isoform of Troponin T
(TNNT2) (clone 13211, Thermo Fisher scientific) labeled with
Alexa-488 using Zenon technology (Invitrogen). The staining
was performed in PBS with 5% FCS and 0.75% Saponin
(Sigma). Stained cells were analyzed and sorted on an AriaII flow
cytometer (BD). Data was collected from at least 10,000 events.
For magnetic activated cell sorting (MACS; Milteny), cells were
stained with anti-VCAM1 antibody conjugated with allophyco-
cyanin (APC) followed by anti-APC microbeads (Milteny).
Sorted cells were fixed and stained with TNNT2-alexa-488.
Data were analyzed with DIVA software (BD) or FlowJo
software (Treestar).
For fluorescent microscopy, hiPSC-derived VCAM1-positive
cells were sorted at d11 and recultured on 0.1% gelatin-coated
plates in 10% fetal bovine serum (FBS)/alpha MEM (Invitrogen)
for 5–7 days. Cells were stained for TNNT2, or sarcomeric a-
actinin (Sigma) with DAPI.
Surface screening of cardiomyocytes derived from hiPSCs
50,000 harvested cells were stained with each antibody from
Lyoplate human cell surface marker screening panel (BD),
followed by anti-Mouse IgG conjugated with Alexa-647 or anti-
Rat IgG conjugated with Alexa-647. Cells stained with surface
marker were fixed by 4% PFA, and stained with TNNT2-antibody
labeled with Alexa-488 using zenon technology. Stained cells were
analyzed on an LSRFortessa equipped with a High Throughput
Sampler (BD).
Quantitative reverse transcription polymerase chain
reaction
Total RNA was prepared with the RNeasy mini kit. 500 ng
RNA was reverse transcribed into cDNA via random hexamers
and Oligo (dT) with Superscript III Reverse Transcriptase
SuperMix (Invitrogen). Quantitative Real-time PCR (qPCR)
was performed on a StepOne Plus (Applied Biosystems). All
experiments were performed in biological triplicate with TaqMan
fast advanced master mix (Applied Biosystems). qPCR was
performed for at least three independent experiments at each
time point. All TaqMan probes listed in Table 2 were purchased
from Applied Biosystems. Expression level was calculated by the
ddCt method and normalized to ribosomal 18S RNA and
indicated time point.
To demonstrate transgene expression, qPCR was performed
with Power SYBR Green PCR master mix (Applied Biosystems)
and primers as reported previously [7]. Expression level was
compared to human dermal fibroblast (HDF) 7 days after the
transduction with the four retroviruses (HDF/4f-7d) [7].
Electrophysiological studies
Electrophysiological studies were carried out as previously
described [10,11]. Briefly, VCAM1-positive cells after 11 days of
induction were collected by MACS sorting and re-seeded on
Table 2. TaqMan probe list.
Gene symbol Probe id
18S Hs99999901_s1
NANOG Hs02387400_g1
POU5F1 Hs03005111_g1
T Hs00610080_m1
MESP1 Hs00251489_m1
KDR Hs00911700_m1
ISL1 Hs01099687_m1
NKX2-5 Hs00231763_m1
MYH6 Hs00411908_m1
MYH7 Hs01110632_m1
MYL2 Hs00166405_m1
MYL7 Hs00221909_m1
TNNT2 Hs00165960_m1
VCAM1 Hs01003372_m1
doi:10.1371/journal.pone.0023657.t002
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PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23657Figure 2. Cell surface marker screening. (A) Classification of cell surface markers and schematic dot plot diagrams for each class. (B) Exclusive
expression pattern of TNNT2 and PDGFRb (Class 3) (C) Concordant expression pattern of TNNT2 and VCAM1 (Class 4). (D) qPCR of TNNT2 and VCAM1.
VCAM1 was expressed concordantly with the cardiac gene. (E–I) Representative flow-cytometry analysis. (E) Expression time course of TNNT2 and
VCAM1. (F) VCAM1 expression in TNNT2-positive cells. (G–I) Dot plots of VCAM1 and TRA-1-60 (undifferentiated hESC/hiPSC marker) at day 0 and 11
(G), PDGFRb (mesoderm/pericyte marker) (H), and VE-cadherin (endothelial marker) (I) at day 11. These markers were exclusively expressed.
doi:10.1371/journal.pone.0023657.g002
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PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23657Figure 3. Purification of cardiomyocytes with VCAM1. (A) Representative flow-cytometry histogram of pre- and post-MACS purification with
VCAM1 at d11. (B) Purity of VCAM1- and TNNT2-positive cells after MACS purification with VCAM1. 98.261.3% and 95.662.5% of sorted cells were
positive for VCAM1 and TNNT2, respectively (n=6). (C) qPCR for cardiac marker genes. Open bars: MACS-purified VCAM1-positive cells. Closed bars:
control (FACS-purified VCAM1-negative cells). (D) Fluorescent staining of purified VCAM1 stained with TNNT2 or a-actinin. Clear sarcomere structures
were observed. (E) Electrophysiological study of single VCAM1-positive cell. Action potentials with ventricular-like pattern (left) and pacemaker-like
pattern (right).
doi:10.1371/journal.pone.0023657.g003
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cells were cultured for 7–8 days under this condition before use.
The coverslips were then transferred to a patch clamp recording
chamber, and electrophysiological measurements were carried out
using Axopatch200B amplifier and Digidata 1440A interface
(Molecular Devices, CA). Self beating cells were selected for this
study.
Composition of Solutions. Physiological bathing solution
contained (in mM) 140 NaCl, 5.4 KCl, 1.8 CaCl2, 1.0 MgCl2,
0.33 NaH2PO4, 5 dextrose, and 10 HEPES, adjusted to pH 7.40
with NaOH. Pipette solution contained 135 KCl, 5 Na2 creatine
phosphate, 5 MgATP and 10 HEPES, adjusted to pH 7.20 with
KOH. The electrode resistance was 4–6 MOhm. The action
potential recordings were carried out at 29–31uC. The temper-
ature was measured at the beginning of each cell measurement
(approximately every 30 min).
Results
Efficient induction of cardiomyocytes from hiPSCs
hiPSCs (201B6) were differentiated toward cardiomyocytes
using modified-directed differentiation protocol (Method,
Figure 1A). This differentiation method was based on a previous
report [1] with the following modifications. Firstly, matrigel was
added prior to induction to support cell survival during
differentiation following a recent report (Zhang, Circulation,
2010: Abstract A20724). Secondly, we further added bFGF
during d1-5 to enhance mesoderm differentiation and Dkk1
during d5-7 to improve cardiac differentiation from mesoderm
[2,12]. Beating clusters were first observed at day 8–9 and spread
by day 11 after induction (Movie S1). TNNT2-positive cells
appeared at day 7–8 after induction and were increased up to
30–70% (48612%, n=17) of total cells at day 11 (Figure 1B)
whereas only 10% of cells from 201B6 were positive for TNNT2
without these modifications (Data not shown). qPCR analysis
reflected the differentiation processes from an undifferentiated
state to cardiomyocytes (Figure 1C–F). Rapid downregulation of
pluripotent stem cell markers such as NANOG and POU5F1
(Figure 1C) was observed within two days of differentiation.
Early and cardiac mesodermal genes (T, MESP1, KDR, ISL1)
were expressed during day 2–5 (Figure 1D and E) and cardiac
genes (NKX2-5, MYH6, MYH7, MYL2,a n dMYL7) were
expressed after day 7 (Figure 1F). Though very faint expressions
of the OCT3/4 and SOX2 transgenes were detected by qPCR
after day 5 (data not shown), the expression level of total Oct3/4
and Sox2 mRNA continued to be suppressed after differentia-
tion, suggesting that reactivation of transgenes should be
functionally negligible.
VCAM1 is specifically expressed on cardiomyocytes
derived from hiPSCs
Using this efficient method, we screened 242 anti-human
antibodies (Lyoplate human cell surface marker screening panel
(BD)) of cell surface markers on TNNT2-positive cells at day 11
after induction. We co-stained total cells at day 11 with anti-
TNNT2 antibody and one of the antibodies in the library, and
examined their expression pattern with flow cytometry. We
classified the antibodies into four groups as class 1: no expression,
class 2: non-specific, class 3: non-cardiac, and class 4: cardiac
expression (Figure 2A; Dataset S1). Among them, 154 and 48
antibodies were classified as class 1 and 2. Thirty-nine antibodies
including some undifferentiated ESC, endothelial, hematopoietic,
and pericyte markers were classified as class 3 (Figure 2A and B).
Only one antibody, anti-CD106 (vascular cell adhesion molecule
1; VCAM1) antibody was classified as class 4 (Figure 2C).
We further characterized VCAM1 as a cardiomyocyte marker.
qPCR revealed that the expression of VCAM1 appeared at day 7–
9 after induction (Figure 2D). Detailed expression time course of
VCAM1 and TNNT2 by flow cytometry revealed TNNT2
expression preceded VCAM1 appearance (Figure 2E). A small
number of TNNT2-positive cells were positive for VCAM1 at day
7 and double positive cells increased to approximately 80% of
TNNT2-positive cells by day 11 (Figure 2E and F). VCAM1/
TNNT-double positive cells should represent a later stage
cardiomyocytes than VCAM1-negative/TNNT-positive cells.
Importantly, VCAM1 expression was mutually exclusive with
an undifferentiated hESC/hiPSC marker, TRA-1-60, and a
mesoderm and vascular pericyte marker, platelet-derived growth
factor receptor beta (PDGFRb/CD140b) (Figure 2G and H).
Though VCAM1 was reported to be expressed on cytokine-
activated endothelium, an endothelial marker, CD144 (VE-
cadherin) and VCAM1 were also mutually exclusive in our study
(Figure 2I). Thus, VCAM1 is an exclusive marker of cardiomy-
ocytes appearing shortly after TNNT2.
Purification of cardiomyocytes from hiPSC culture with
VCAM1
Next, we purified VCAM1-positive cells by MACS at d11.
VCAM1-positive cells were obtained by MACS with around 98%
purity (98.261.3%, n=6). Approximately 95% (95.662.5%,
n=6) of purified cells were positive for TNNT2 (Figure 3A and
B). 5210610
5 VCAM1-positive cells were sorted from a single
well of a six-well culture plate in which 10610
5 undifferentiated
hiPSCs were plated. Purified VCAM1-positive cells at day 11
highly expressed various mRNAs of cardiac genes compared with
control (FACS-purified VCAM1-negative cells) (Figure 3C). Re-
cultured VCAM1-positive cells showed structural and functional
cardiomyocyte features such as clear sarcomere formation
(Figure 3D), self-beating (Movie S2) and action potentials
resembling ventricular and pacemaker cells (Figure 3E and
Table 3). Thus, human cardiomyocytes can be highly purified
with this antibody even with MACS.
VCAM1 is a robust marker for cardiomyocytes from
various human ESC and iPSC lines
To further demonstrate the utility of this method, we evaluated
several hESC/hiPSC lines (Figure 4). TNNT2-positive cardiomy-
ocytes were induced from a hESC line (KhES1) and three hiPSC
lines (253G1, 253G4, 201B7) with 4.1–34.3% efficiency. Differ-
entiation efficiencies of these lines were lower than that of 201B6,
but were not related to their derivation methods. VCAM1
specifically marked a subset of TNNT2-positive cells, but
Table 3. Summary for EPS.
Parameter mean±SD (n=49)
Peak (mV) 28.9611.4
Maximum diastolic potential (mV) 256.366.6
Amplitude (mV) 85.2616.4
Action potential duration 50 (msec) 2226111
Action potential duration 30 (msec) 162685
dV/dt (mV/msec) 33.469.4
Mean cycle length (sec) 1.1360.97
doi:10.1371/journal.pone.0023657.t003
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varied from 33% to 64%, reflecting differences in cardiomyocyte
differentiation and maybe maturation propensities among cell
lines [13]. Even with such variations, TNNT2-positive cardiomy-
ocytes could be highly purified with VCAM1 in various human
pluripotent stem cell lines (.95%) (Figure 4). Thus we conclude
that VCAM1 is a very useful marker to purify cardiomyocytes
derived from hESCs and hiPSCs.
Discussion
Here we reported an efficient cardiomyocyte induction method
from hESCs/hiPSCs and demonstrated VCAM1 as a potent
surface marker for cardiomyocytes induced with this method.
Some purification methods have been previously established [14–
16]. Tetramethylrhodamine methyl ester perchlorate, a mito-
chondrial fluorescent dye could selectively enrich hESC/hiPSC-
derived cardiomyocytes (.99% purity) by fluorescence-activated
cell sorting (FACS) [14]. As this technique depends on FACS
purification, there is a scale limitation due to cell sorting capacity.
ALCAM was reported as a cell surface marker for cardiomyocytes
derived from a mouse embryo and hESCs [15,17]. ALCAM is also
expressed on other cell types, thus, purity using MACS was
relatively low (.85%). A genetic approach, which would not be
applicable for clinical purpose, was also reported using drug
selection with lenti-viral vector that encodes a drug resistant gene
[16]. After myocardial infarction, up to 10
9 cardiomyocytes would
be lost in human. Our method, with which we can highly purify
cardiomyocytes with cell surface marker VCAM1 using MACS, is
a scalable, selective and non-genetic method to prepare cardio-
myocytes for clinical purpose.
With this method, a very small subset of TNNT2-negative, non-
cardiomyocyte population was still observed in MACS-purified
VCAM1-positive cells (,5%). Currently, the identity of VCAM1-
positive/TNNT2-negative cells is still unclear. VCAM1 was
negative for undifferentiated hESCs/hiPSCs, a mesoderm and
vascular pericyte marker, PDGFRb/CD140b, and an endothelial
marker, CD144 (VE-cadherin) (Figure 2G–I). VCAM1 expression
is reported in developing allantois and the heart [18], and bone
marrow stroma [19]. Thus, VCAM1-positive/TNNT2-negative
cells should probably be mesoderm derivatives or mesenchymal
lineage cells, but should not include undifferentiated cells.
To apply this method for clinical application, transplantation
methods should be developed. Regenerative potential and side
effects such as tumor formation should be examined in each
transplantation method. There was almost no undifferentiated cell
contamination after purification, but safety issue in our method
should be confirmed before moving to clinical usage. Nevertheless,
this efficient cardiomyocyte induction method and a potent cell
surface marker for robust, efficient and scalable purification of
cardiomyocytes from hESCs/hiPSCs would offer a valuable
technological basis for future cardiac cell therapy using hESCs/
hiPSCs.
Supporting Information
Dataset S1 Results of cell surface marker screening.
Percentages of each quadrant, classification and antibody
information for each antibody are shown.
(XLS)
Movie S1 Beating clusters at day 11 after induction.
(MP4)
Movie S2 Single beating cell at day 5 after VCAM1
sorting.
(MP4)
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